Tags

Type your tag names separated by a space and hit enter

The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women.
Clin Endocrinol (Oxf). 2003 Jun; 58(6):704-9.CE

Abstract

OBJECTIVE

To assess the effect of a dietary soy protein supplement containing isoflavones on lipids and indices of bone resorption in postmenopausal women.

DESIGN

Placebo-controlled, double-blind, randomized study.

PATIENTS

One hundred and six postmenopausal women were randomized to dietary soy supplementation (n = 51) or placebo (n = 55) for 3 months, of which 78 were included in the final analysis.

MEASUREMENTS

Lipid profiles including total, low-density lipoprotein (LDL) and HDL cholesterol as well as triacylglycerol were measured. Pyridinoline and deoxypyridinoline were used as markers of bone resorption. Urinary isoflavone excretion was measured to assess compliance.

RESULTS

There was a significantly greater increase in urinary isoflavone excretion detected in the soy group compared to placebo. Lipid profiles improved with significant decreases in LDL cholesterol (-0.60 +/- 0.10 vs.-0.29 +/- 0.09 mmol/l, P < 0.05), triacylglycerol (-0.22 +/- 0.07 vs. +0.01 +/- 0.05 mmol/l, P < 0.005) and the LDL : HDL ratio (-0.32 +/- 0.10 vs. +0.20 +/- 0.10, P < 0.005) in the soy group compared to placebo. There were no significant differences between the soy and placebo groups for urinary excretion of pyridinoline (-3.8 +/- 3.1 vs.-0.8 +/- 3.1 nmol/mmolCr, P = 0.4) or deoxypyridinoline (-0.8 +/- 0.9 vs.-0.3 +/- 0.7 nmol/mmolCr, P = 0.4).

CONCLUSIONS

In postmenopausal women, dietary supplementation with soy protein containing isoflavones does not appear to have oestrogenic effects on markers of bone resorption. Soy protein favourably affected lipids; however, these effects (fall in triacylglycerol and no change in HDL) differ from those observed with oral oestrogen. These findings suggest that soy may not have biologically significant oestrogenic effects on bone resorption and we hypothesize that the lipid effects may be mediated, at least in part, through nonoestrogenic mechanisms.

Authors+Show Affiliations

Department of Epidemiology and Preventive Medicine, Monash University, The Alfred Hospital, Prahran, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12780746

Citation

Dalais, Fabien S., et al. "The Effects of Soy Protein Containing Isoflavones On Lipids and Indices of Bone Resorption in Postmenopausal Women." Clinical Endocrinology, vol. 58, no. 6, 2003, pp. 704-9.
Dalais FS, Ebeling PR, Kotsopoulos D, et al. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol (Oxf). 2003;58(6):704-9.
Dalais, F. S., Ebeling, P. R., Kotsopoulos, D., McGrath, B. P., & Teede, H. J. (2003). The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clinical Endocrinology, 58(6), 704-9.
Dalais FS, et al. The Effects of Soy Protein Containing Isoflavones On Lipids and Indices of Bone Resorption in Postmenopausal Women. Clin Endocrinol (Oxf). 2003;58(6):704-9. PubMed PMID: 12780746.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. AU - Dalais,Fabien S, AU - Ebeling,Peter R, AU - Kotsopoulos,Dimitra, AU - McGrath,Barry P, AU - Teede,Helena J, PY - 2003/6/5/pubmed PY - 2003/8/26/medline PY - 2003/6/5/entrez SP - 704 EP - 9 JF - Clinical endocrinology JO - Clin Endocrinol (Oxf) VL - 58 IS - 6 N2 - OBJECTIVE: To assess the effect of a dietary soy protein supplement containing isoflavones on lipids and indices of bone resorption in postmenopausal women. DESIGN: Placebo-controlled, double-blind, randomized study. PATIENTS: One hundred and six postmenopausal women were randomized to dietary soy supplementation (n = 51) or placebo (n = 55) for 3 months, of which 78 were included in the final analysis. MEASUREMENTS: Lipid profiles including total, low-density lipoprotein (LDL) and HDL cholesterol as well as triacylglycerol were measured. Pyridinoline and deoxypyridinoline were used as markers of bone resorption. Urinary isoflavone excretion was measured to assess compliance. RESULTS: There was a significantly greater increase in urinary isoflavone excretion detected in the soy group compared to placebo. Lipid profiles improved with significant decreases in LDL cholesterol (-0.60 +/- 0.10 vs.-0.29 +/- 0.09 mmol/l, P < 0.05), triacylglycerol (-0.22 +/- 0.07 vs. +0.01 +/- 0.05 mmol/l, P < 0.005) and the LDL : HDL ratio (-0.32 +/- 0.10 vs. +0.20 +/- 0.10, P < 0.005) in the soy group compared to placebo. There were no significant differences between the soy and placebo groups for urinary excretion of pyridinoline (-3.8 +/- 3.1 vs.-0.8 +/- 3.1 nmol/mmolCr, P = 0.4) or deoxypyridinoline (-0.8 +/- 0.9 vs.-0.3 +/- 0.7 nmol/mmolCr, P = 0.4). CONCLUSIONS: In postmenopausal women, dietary supplementation with soy protein containing isoflavones does not appear to have oestrogenic effects on markers of bone resorption. Soy protein favourably affected lipids; however, these effects (fall in triacylglycerol and no change in HDL) differ from those observed with oral oestrogen. These findings suggest that soy may not have biologically significant oestrogenic effects on bone resorption and we hypothesize that the lipid effects may be mediated, at least in part, through nonoestrogenic mechanisms. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/12780746/The_effects_of_soy_protein_containing_isoflavones_on_lipids_and_indices_of_bone_resorption_in_postmenopausal_women_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0300-0664&amp;date=2003&amp;volume=58&amp;issue=6&amp;spage=704 DB - PRIME DP - Unbound Medicine ER -